



Review

Coexistence of central precocious puberty and intraventricular arachnoid cyst: a brief literature update

Gonzalo Oliván-Gonzalvo ^{a,*} , Vicente Calatayud-Maldonado ^b

^a *Pediatrics and International Adoption Centre, Zaragoza, Spain*

^b *Neurosciences Institute of Aragón, Zaragoza, Spain*

ARTICLE INFO

Article history:

Received 13 November 2020

Received in revised form 10 December 2020

Accepted 14 December 2020

Keywords:

Central precocious puberty
Intraventricular arachnoid cyst
Children
Rare diseases
GnRH test
Brain MRI
Surgery
GnRH analogs

ABSTRACT

Central precocious puberty (CPP) is a rare disease. The mean annual incidence in girls is 0.8-1.1/100,000 and in boys 0-0.1/100,000. Intracranial arachnoid cysts (ICACs) are usually congenital and represent 1% of intracranial masses in newborns. Intraventricular location is rare. The objective of this work is to carry out a literature updated review of the coexistence of CPP and intraventricular arachnoid cyst (IVAC). ICACs are usually asymptomatic but can present with CPP in 10-40% of patients. IVACs represents only 0.3-1.4% of ICACs, and most seemed originate from the velum interpositum cistern. CPP in girls is usually idiopathic, while in 30-70% of boys are due to an intracranial lesion. Therefore, the coexistence of PPC and IVAC is very rare in boys and exceptional in girls. The exact mechanism of a cyst's influence on the hypothalamic-pituitary axis is not completely understood. Theories include increased ventricular volume, associated mass effect on the hypothalamus, and direct compression of portions of the hypothalamic-pituitary axis. Analysis of LH peaks after GnRH testing is the gold standard for the diagnosis of CPP. Brain MRI should be part of the assessment in boys and also in girls since clinical features, including age and sex, are not helpful in predicting those with underlying brain pathology. In cases of CPP with IVAC, surgery does not have any effect on the course of pubertal development. The indication for surgery is the onset of neurological symptoms. The medical treatment selected, safe and effective, is GnRH analog depot preparations. In conclusion, there seems to be a consensus for the diagnosis and management of the coexistence of CPP and IVAC, but the etiopathogenesis is not yet well recognized.

© 2021 The Authors. Published by Iberoamerican Journal of Medicine. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

HOW TO CITE THIS ARTICLE: Oliván-Gonzalvo G, Calatayud-Maldonado V. Coexistence of central precocious puberty and intraventricular arachnoid cyst: a brief literature update. *Iberoam J Med.* 2021;3(1):65-70. doi: 10.5281/zenodo.4323287.

1. INTRODUCTION

Precocious puberty is defined as the development of secondary sex characteristics before the age of 8 years in girls and 9 years in boys, which is accompanied by bone

age advancement and growth spurt. Two types of precocious puberty are recognised, central precocious puberty (CPP) and peripheral precocious puberty [1]. CPP is caused by early activation of the hypothalamic-pituitary axis, with gonadotropin-releasing hormone (GnRH)-

* Corresponding author.

E-mail address: golivang@gmail.com

ISSN: 2695-5075 / © 2021 The Authors. Published by Iberoamerican Journal of Medicine. This is an open access article under the CC BY license

(<http://creativecommons.org/licenses/by/4.0/>).

<http://doi.org/10.5281/zenodo.4323287>

stimulated gonadotropin secretion causing gonadal maturation [2]. In peripheral precocious puberty, serum sex steroid levels are elevated independently of gonadotropin secretion, and the gonads do not undergo maturation [3]. Precocious puberty may be isosexual (involving secondary sex characteristics that are gender matched) or heterosexual (involving sex characteristics of the opposite gender). CPP is always isosexual, whereas peripheral precocious puberty may be isosexual or heterosexual [1-3].

Intracranial arachnoid cysts (ICACs) are considered benign developmental anomalies that occur within the arachnoid membrane that undergoes a splitting and traps cerebrospinal fluid inside. In most cases, they are congenital, and usually do not cause any symptoms throughout an individual's life [4, 5]. In cases in which symptoms occur, headaches, nausea, vomiting, dizziness and hydrocephalus are common. Rarely cause malformation of certain cranial bones, resulting in macrocephaly [6, 7]. A variety of additional symptoms occurs in some children depending upon the size and location of the cyst. Such symptoms include lethargy, seizures, hemiparesis, ataxia, vision abnormalities, hearing abnormalities, developmental delays, behavioral changes, cognitive impairment, and difficulties with balance and walking [4-7]. ICACs can also present with variable endocrine manifestations, although only 10% to 40% of patients have CPP [8-14]. Intraventricular location is rare, account less than 1% of the total ICACs [4, 5].

The objective of this work is to carry out a literature updated review of the coexistence of CPP and intraventricular arachnoid cyst (IVAC).

2. EPIDEMIOLOGY

The mean annual incidence rates of CPP in girls ranging from 0.8 to 1 per 100,000 girls. The incidence in boys is approximately 10- to 15-fold lower. In Spain, the global prevalence of CPP is 0.00019 (girls: 0.00037; boys: 0.000046), with an annual incidence ranging from 0.02 and 1.07 new cases per 100,000 (girls: 0.13- 2.17; boys: 0-0.23) and an incidence rate from 1997 to 2009 of 5.66 cases per million people at risk / year (girls: 11.23; boys: 0.96). Therefore, CPP is a rare disease with a clear female predominance (approximately 10:1) [15].

ICACs account for roughly 1% of intracranial masses in newborns. The most frequent location is the middle fossa (30-60%), followed by the sellar and suprasellar region (10-20%), the quadrigeminal cistern (10%), the cerebellopontine angle (10%), and the vermis (9%). The remaining occurs in other regions. Intraventricular location

is rare, in both children and adults, and represents less than 1% of the total [4, 5, 10, 13, 14, 16]. In fact, Al-Holou et al. [7] reported only 0.3% located in the ventricle among 309 cases of ICACs, and Shim et al. [6] reported only 1.4% among 209 cases.

Therefore, the coexistence of CPP and intraventricular arachnoid cyst (IVAC) is very rare in boys and exceptional in girls. The etiopathogenesis is not well recognized.

3. ETIOPATHOGENESIS

CPP may be idiopathic or related to a central nervous system lesion such as a neoplasm, cyst, trauma, infection, midline anomalies and hydrocephalus. CPP in girls is usually idiopathic, whereas, most cases in boys are due to an intracranial lesion [1, 2, 17]. The prevalence of intracranial lesion ranges from 30% to 70% in boys, and from 7% to 15% in girls, depending on the series [13, 16, 18-26].

CPP involves activation of the hypothalamic-pituitary-gonadal axis such that GnRH released from the hypothalamus causes gonadotropin secretion by the pituitary gland, leading to ovulation or spermatogenesis. The exact mechanism of a cyst's influence on the hypothalamic-pituitary axis is not completely understood. A general concept is disruption of the normal influence of the hypothalamus on the pituitary gland [27]. One hypothesis is based on mass effect of the cyst on the hypothalamus [8, 28]. Theories regarding the role of hydrocephalus in CPP include increased ventricular volume and associated mass effect on the hypothalamus, as well as direct compression of various portions of the hypothalamic-pituitary axis [27, 29].

IVACs represent simple cystic structures. The origin of these lesions is controversial, since the ventricles are lined with ependyma and not containing arachnoid membranes. Researchers have suggested that the origin seems to be secondary to the displacement of arachnoid cells by the vascular mesenchyma through the choroidal fissure during the process of choroid plexus development. In some cases, it seems to be secondary to an extension of a subarachnoid arachnoid cyst through the choroidal fissure and into the lateral ventricle [5, 30, 31].

More recently, in 2016, Knie et al. [32], analyzing follow-up neuroimages after neuroendoscopic cyst fenestration findings suggest that the IVACs were either originating from the velum interpositum cistern or from the quadrigeminal cistern. Based on this theory an arachnoid cyst that has its origin laterally may extent through the choroidal fissure to the lateral ventricle when growing. As

the lateral ventricle is larger than the velum interpositum cistern, this cyst becomes more prominent. Arachnoid cysts of the quadrigeminal cistern have a close relationship to the posterior midbrain, which causes distortion or compression of the aqueduct leading to hydrocephalus, whereas in cysts deriving from the velum interpositum cistern hydrocephalus is a rare finding. Histologically, the cyst wall has arachnoid origin but can be covered with the ependymal layer when it protrudes into the lateral ventricle through the choroidal fissure. Knie et al. [32] suggest that based on the analysis of neuroimaging, it would be possible to describe the origin of an arachnoid cyst beforehand. They differentiated cysts originating from velum interpositum cistern from those originating from the quadrigeminal cistern by the long axis of the cyst. A cyst originating from the velum interpositum cistern is usually located parietal at the long axis of the ventricle. A quadrigeminal cyst extends from the midbrain in a parietal direction towards the corpus callosum. During its extension, it can grow laterally into the lateral ventricle, and thus mimicking a velum interpositum cyst. These researchers concluded that most IVACs seemed to originate from the velum interpositum cistern and some

seemed to extend from the quadrigeminal cistern.

4. DIAGNOSIS

For the diagnosis of CPP, hormone studies are needed in addition to the clinical data regarding signs of pubertal onset. Analysis of LH peaks after GnRH testing is the gold standard in the biochemical diagnosis. Imaging studies, such as bone age, pelvic ultrasound and brain magnetic resonance imaging (MRI), are also very useful. Furthermore, genetic testing must be incorporated in familial cases [21, 24]. See the diagnostic algorithm for CPP in girls (Figure 1) and boys (Figure 2).

Traditionally, CPP has been characterized by the increase of estradiol (girls), testosterone (boys) and an LH peak after stimulation with GnRH or GnRH analogues (GnRHa) (leuprolide acetate) testing in both sexes. Currently, regardless of the protocol employed, the threshold of LH peak to consider activation of puberty ranges between > 5 and 8 IU/L. A basal LH/FSH ratio of ≥ 0.2 (> 0.66 after stimulation) has been recently postulated as an indicator of pubertal activation. Nevertheless, its sensitivity and




Figure 1: Diagnostic algorithm of CPP in girls.

CPP: Central precocious puberty; GnRH: Gonadotropin-releasing hormone; GnRHa: Gonadotropin-releasing hormone analogue; LH: Luteinizing hormone; MRI: Magnetic resonance imaging.

specificity do not reach that of the GnRH-stimulated LH peak. Testosterone is a useful tool in the diagnosis of precocious puberty in boys and testosterone values in the prepubertal range rule out CPP. Conversely, low estradiol levels in girls do not reject the diagnosis of CPP. In addition, although the analysis of pulsatile secretion of estradiol could be more sensitive than that of isolated estradiol determinations, this test does not achieve the utility of GnRH test in the diagnosis of CPP [1, 2, 21, 23, 24].

The bone age is notably greater than the chronological age compared to normal variants of puberty. Notwithstanding, in the early phases of CPP this advance may not be very striking. The main utility of pelvic ultrasound is to detect changes in uterine and ovarian dimensions due to estrogen exposure, and ovarian tumors or cysts that can cause an increase in estradiol production [1, 2, 24].

CPP is more common by far in girls than in boys. Although

central nervous system disorders account for a higher percentage of cases in boys but must also be excluded in girls. Thus, girls with CPP should have a brain MRI scan as part of their assessment since clinical features, including age, are not helpful in predicting those with underlying pathology [20, 25, 26, 33, 34]. Brain MRI is the modality of choice to fully characterize ICACs. On neuroimaging, regardless of histology, arachnoid cysts are characterized as smooth, well-circumscribed lesions, with an imperceptible wall, displacing adjacent structures, and following the cerebrospinal fluid pattern (hypodense on CT and hyperintense on T2 with FLAIR suppression on MRI) (Figure 3). They can also have a remodeling effect on the adjacent bone. Arachnoid cyst in the lateral ventricle is commonly associated with focal enlargement of the lateral ventricle by the cyst with or without partial ventriculomegaly. The shape of the cyst is round or oval, not irregular [4-7, 10, 13, 14, 16].




Figure 2: Diagnostic algorithm of CPP in boys.

CPP: Central precocious puberty; GnRH: Gonadotropin-releasing hormone; GnRHα: Gonadotropin-releasing hormone analogue; LH: Luteinizing hormone; MRI: Magnetic resonance imaging.




Figure 3: Brain magnetic resonance imaging. A) Axial FLAIR image: the intraventricular cyst shows the typical water-like loss of signal, confirming its cerebrospinal fluid content. B) Axial T2-weighted image: a thin-walled hyperintense cerebrospinal fluid-like cyst inside the left ventricle is seen.

5. MANAGEMENT

In CPP cases secondary to central nervous system lesions, the etiological treatment, such as surgery, would not have any effect on the course of pubertal development [1, 2]. Controversy remains about when surgery is indicated and which procedures to choose. There seems to be a consensus that in pediatric patients the indication for surgery is seizure onset, hydrocephalus, ruptured/hemorrhaged, and mass effect or slow growing clinical course [6, 32, 35].

The use of intramuscular GnRHa depot preparations (triptorelin or leuprolide) every 28 days is the medical treatment selected for CPP. This compound stems from a chemical substitution at position 6 and 10 of the native GnRH molecule, it has a decreased enzymatic degradation and in parallel, an increased affinity for the GnRH-pituitary receptor resulting in desensitization of the receptor. Consequently, this action produces an inhibition of gonadotropin secretion [36].

On the optimal age to withdraw the GnRHa treatment in girls, with the aim of menarche emerging near to the age of the normal population, we should evaluate whether to discontinue the treatment around 10 years of chronological age or 12 years of bone age. In this regard, spontaneous

menses appears around 12 months after GnRHa withdrawal. In boys, we should make a decision around 11-11.5 years of chronological age. The available evidence shows that GnRHa is safe and effective, and long-term data suggests that reproductive function is satisfactory after discontinuation of treatment [24, 25, 36, 37].

6. REFERENCES

- Carel JC, Léger J. *Clinical practice. Precocious puberty.* *N Engl J Med.* 2008;358(22):2366-77. doi: 10.1056/NEJMcp0800459.
- Soriano-Guillén L, Argente J. *Central precocious puberty: epidemiology, etiology, diagnosis and treatment.* *An Pediatr (Barc).* 2011;74(5):336.e1-336.e13. doi: 10.1016/j.anpedi.2010.11.003.
- Soriano Guillén L, Argente J. *Peripheral precocious puberty: clinical, diagnostic and therapeutical principles.* *An Pediatr (Barc).* 2012;76(4):229.e1-229.e10. doi: 10.1016/j.anpedi.2011.09.014.
- Gelabert-González M. *Intracranial arachnoid cysts.* *Rev Neurol.* 2004;39(12):1161-6.
- Cincu R, Agrawal A, Eiras J. *Intracranial arachnoid cysts: current concepts and treatment alternatives.* *Clin Neurol Neurosurg.* 2007;109(10):837-43. doi: 10.1016/j.clineuro.2007.07.013.
- Shim KW, Lee YH, Park EK, Park YS, Choi JU, Kim DS. *Treatment option for arachnoid cysts.* *Childs Nerv Syst.* 2009;25(11):1459-66. doi: 10.1007/s00381-009-0930-7.
- Al-Holou WN, Yew AY, Boomsaad ZE, Garton HJ, Muraszko KM, Maher CO. *Prevalence and natural history of arachnoid cysts in children.* *J Neurosurg Pediatrics.* 2010;5(6):578-85. doi: 10.3171/2010.2.PEDS09464.
- Mohn A, Schoof E, Fahlbusch R, Wenzel D, Dörr HG. *The endocrine spectrum of arachnoid cysts in childhood.* *Pediatr Neurosurg.* 1999;31(6):316-21. doi: 10.3171/2017.1.PEDS16404.
- Adan L, Bussièrès L, Dinand V, Zerah M, Pierre- Kahn A, Brauner R. *Growth, puberty and hypothalamic-pituitary function in children with suprasellar arachnoid cyst.* *Eur J Pediatr.* 2000;159(5):348-55. doi: 10.1007/s004310051285.
- Starzyk J, Kwiatkowski S, Urbanowicz W, Starzyk B, Harasiewicz M, Kalicka-Kasprczyk A, et al. *Suprasellar arachnoid cyst as a cause of precocious puberty: report of three patients and literature overview.* *J Pediatr Endocrinol Metab.* 2003;16(3):447-55. doi: 10.1515/jpem.2003.16.3.447.
- Trivin C, Couto-Silva AC, Sainte-Rose C, Chemaitilly W, Kalifa C, Doz F, et al. *Presentation and evolution of organic central precocious puberty according to the type of CNS lesion.* *Clin Endocrinol (Oxf).* 2006;65(2):239-45. doi: 10.1111/j.1365-2265.2006.02582.x.
- Savas Erdevi S, Ocal G, Berberoglu M, Siklar Z, Hacıhamdioglu B, Evliyaoglu O, et al. *The endocrine spectrum of intracranial cysts in childhood and review of the literature.* *J Pediatr Endocrinol Metab.* 2011;24(11-12):867-75. doi: 10.1515/jpem.2011.263.
- Chung EM, Biko DM, Schroeder JW, Cube R, Conran RM. *From the radiologic pathology archives: precocious puberty: radiologic-pathologic correlation.* *Radiographics.* 2012;32(7):2071-99. doi: 10.1148/rg.327125146.
- Lee JY, Lee YA, Jung HW, Chong S, Phi JH, Kim SK, et al. *Long-term endocrine outcome of suprasellar arachnoid cysts.* *J Neurosurg Pediatr.* 2017;19(6):696-702. doi: 10.3171/2017.1.PEDS16404.
- Soriano-Guillén L, Corripio R, Labarta JI, Cañete R, Castro-Feijóo L, Espino R, et al. *Central precocious puberty in children living in Spain: incidence, prevalence, and influence of adoption and immigration.* *J Clin Endocrinol Metab.* 2010;95(9):4305-13. doi: 10.1210/jc.2010-1025.
- Faizah M, Zuhani A, Rahmah R, Raja A, Wu L, Dayang A, et al. *Precocious puberty in children: A review of imaging findings.* *Biomed Imaging Interv J.* 2012;8(1):e6. doi: 10.2349/bijj.8.1.e6.
- Martín Díaz MJ, Soriano Guillén L, Muñoz Calvo MT, Pozo Román J, Argente Oliver J. *Central precocious puberty is associated with a high prevalence of organic disease.* *An Pediatr (Barc).* 2006;65(5):434-8. doi: 10.1157/13094249.
- De Sanctis V, Corrias A, Rizzo V, Bertelloni S, Urso L, Galluzzi F, et al. *Etiology of central precocious puberty in males: the results of the Italian Study Group for Physiopathology of Puberty.* *J Pediatr Endocrinol Metab.* 2000;13(suppl 1):687-93. doi: 10.1515/jpem.2000.13.s1.687.
- Fahmy JL, Kaminsky CK, Kaufman F, Nelson MD Jr, Parisi MT. *The radiological approach to precocious puberty.* *Br J Radiol.* 2000;73(869):560-7. doi: 10.1259/bjr.73.869.10884758.
- Ng SM, Kumar Y, Cody D, Smith CS, Didi M. *Cranial MRI scans are indicated in all girls with central precocious puberty.* *Arch Dis Child.* 2003;88(5):414-8. doi: 10.1136/adc.88.5.414.
- Latronico AC, Brito VN, Carel JC. *Causes, diagnosis, and treatment of central precocious puberty.* *Lancet Diabetes Endocrinol.* 2016;4(3):265-74. doi: 10.1016/S2213-8587(15)00380-0.
- Cantas-Orsdemir S, Garb JL, Allen HF. *Prevalence of cranial MRI findings in girls with central precocious puberty: a systematic review and meta-analysis.* *J Pediatr Endocrinol Metab.* 2018;31(7):701-10. doi: 10.1515/jpem-2018-0052.
- Aguirre RS, Eugster EA. *Central precocious puberty: from genetics to treatment.* *Best Pract Res Clin Endocrinol Metab.* 2018;32(4):343-54. doi: 10.1016/j.beem.2018.05.008.
- Soriano-Guillén L, Argente J. *Central precocious puberty, functional and tumor-related.* *Best Pract Res Clin Endocrinol Metab.* 2019;33(3):101262. doi: 10.1016/j.beem.2019.01.003.
- Eugster EA. *Update on precocious puberty in girls.* *J Pediatr Adolesc Gynecol.* 2019;32(5):455-9. doi: 10.1016/j.jpag.2019.05.011.
- Cantas-Orsdemir S, Eugster EA. *Update on central precocious puberty: from etiologies to outcomes.* *Expert Rev Endocrinol Metab.* 2019;14(2):123-30. doi: 10.1080/17446651.2019.1575726.
- Brauner R, Adan L, Souberbielle JC. *Hypothalamic-pituitary function and growth in children with intracranial lesions.* *Childs Nerv Syst.* 1999;15(11-12):662-9. doi: 10.1007/s003810050455.
- Huang HP, Tung YC, Tsai WY, Kuo MF, Peng SF. *Arachnoid cyst with GnRH-dependent sexual precocity and growth hormone deficiency.* *Pediatr Neurol.* 2004;30(2):143-5. doi: 10.1016/S0887-8994(03)00418-1.
- Abdolvahabi RM, Mitchell JA, Diaz FG, McAllister JP 2nd. *A brief review of the effects of chronic hydrocephalus on the gonadotropin releasing hormone system: implications for amenorrhea and precocious puberty.* *Neurol Res.* 2000;22(1):123-6. doi: 10.1080/01616412.2000.11741047.
- Park SW, Yoon SH, Cho KH, Shin YS. *A large arachnoid cyst of the lateral ventricle extending from the supracerebellar cistern--case report.* *Surg Neurol.* 2006;65(6):611-4. doi: 10.1016/j.surneu.2005.07.069.
- Basaldella L, Orvieto E, Dei Tos AP, Della Barbera M, Valente M, Longatti P. *Causes of arachnoid cyst development and expansion.* *Neurosurg Focus.* 2007;22(2):E4. doi: 10.3171/foc.2007.22.2.4.
- Knie B, Morota N, Ihara S, Tamura G, Ogiwara H. *Pediatric intraventricular arachnoid cysts in the body of lateral ventricle: surgical outcome and its embryologic background.* *Childs Nerv Syst.* 2016;32(11):2197-204. doi: 10.1007/s00381-016-3203-2.
- Ng SM, Kumar Y, Cody D, Smith C, Didi M. *The gonadotrophins response to GnRH test is not a predictor of neurological lesion in girls with central precocious puberty.* *J Pediatr Endocrinol Metab.* 2005;18(9):849-52. doi: 10.1515/jpem.2005.18.9.849.
- Mogensen SS, Aksklaede L, Mouritsen A, Sørensen K, Main KM, Gideon P, et al. *Pathological and incidental findings on brain MRI in a single-center study of 229 consecutive girls with early or precocious puberty.* *PLoS One.* 2012;7(1):e29829. doi: 10.1371/journal.pone.0029829.
- Ali M, Bennardo M, Almenawer SA, Zagzoog N, Smith AA, Dao D, et al. *Exploring predictors of surgery and comparing operative treatment approaches for pediatric intracranial arachnoid cysts: a case series of 83 patients.* *J Neurosurg Pediatr.* 2015;16(3):275-82. doi: 10.3171/2015.2.PEDS14612.
- Guaraldi F, Beccuti G, Gori D, Ghizzoni L. *Management of endocrine disease: Long-term outcomes of the treatment of central precocious puberty.* *Eur J Endocrinol.* 2016;174(3):R79-87. doi: 10.1530/EJE-15-0590.
- Kaplowitz PB, Backeljauw PF, Allen DB. *Toward more targeted and cost-effective gonadotropin-releasing hormone analog treatment in girls with central precocious puberty.* *Horm Res Paediatr.* 2018;90(1):1-7. doi: 10.1159/000491103.